Drug
Bardoxolone methyl clinical trials
Also written RTA 402.
- studies test it
- 34
- open now
- 0
- in phase 3
- 7
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Development codes
- RTA 402
- 18
Studies by the year they started
33 studies that test it; most in 2012 (9)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 9 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 15
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 32 · Other 2
Biogen (26) · Kyowa Kirin Co., Ltd. (6) · NYU Langone Health (1) · M.D. Anderson Cancer Center (1)
Studies
Open first, then newest update. How each study uses bardoxolone methyl is read from its arms, and is right about nine times in ten.
Testing it · 34
- A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINALCompletedPhase 2/3BiogenNCT03019185Written as Bardoxolone Methyl
- Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGERTerminatedPhase 3BiogenNCT03068130Written as Bardoxolone methyl
- Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATCompletedPhase 2BiogenNCT02036970Written as Bardoxolone methyl
- Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYSTTerminatedPhase 3BiogenNCT02657356Written as Bardoxolone methyl capsules
- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXCompletedPhase 2BiogenNCT03366337Written as Bardoxolone methyl capsules
- A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)CompletedPhase 2BiogenNCT04702997Written as Bardoxolone methyl oral capsule
- An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)TerminatedPhase 3BiogenNCT03749447Written as Bardoxolone methyl
- A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCONTerminatedPhase 3BiogenNCT03918447Written as Bardoxolone methyl oral capsule
- Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant MelanomaWithdrawnPhase 2BiogenNCT00535314Written as RTA 402 Dose1
- Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic DysfunctionTerminatedPhase 1/2BiogenNCT00550849Written as RTA 402
- Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedPhase 2BiogenNCT00811889Written as Bardoxolone Methyl (RTA 402)
- Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic NephropathyCompletedPhase 2BiogenNCT00664027Written as RTA 402 (Bardoxolone Methyl)
- Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic FunctionCompletedPhase 1BiogenNCT01563562Written as Bardoxolone Methyl
- A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male SubjectsCompletedPhase 1BiogenNCT01503866Written as bardoxolone methyl
- Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval VolunteersCompletedPhase 1BiogenNCT01689116Written as Bardoxolone Methyl 20mg
- Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedPhase 2BiogenNCT01053936Written as Bardoxolone methyl (amorphous dispersion)
- Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy AdultsCompletedPhase 1BiogenNCT03264079Written as Bardoxolone methyl capsules 10 mg
- A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone MethylCompletedPhase 1BiogenNCT01461161Written as bardoxolone methyl
- Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedPhase 1BiogenNCT01549769Written as Bardoxolone Methyl
- Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic CancerTerminatedPhase 1BiogenNCT00529113Written as Bardoxolone methyl
Codes
What other systems call bardoxolone methyl · ClinicalTrials.gg INT004411
- MeSH (NLM) C445068bardoxolone methylConfirmed NLM, Wikidata
- UNII (FDA) CEG1Q6OGU1BARDOXOLONE METHYLConfirmed FDA, NLM, Wikidata
- Wikidata Q4860208bardoxolone methylConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98250Bardoxolone MethylOne source FDA
- DrugBank DB05983One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C445068 | bardoxolone methyl | Confirmed NLM, Wikidata |
| UNII (FDA) | CEG1Q6OGU1 | BARDOXOLONE METHYL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4860208 | bardoxolone methyl | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98250 | Bardoxolone Methyl | One source FDA |
| DrugBank | DB05983 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.